Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis
暂无分享,去创建一个
M. Zhan | S. El-Kamary | H. Alexander | Colleen Reilly | S. Reddy | W. J. Culpepper | A. L. Mindikoglu | B. Lane | Yixing Jiang | Ayse L. Mindikoglu
[1] Hirotaka Chikuda,et al. Perioperative stroke in patients undergoing elective spinal surgery: a retrospective analysis using the Japanese diagnosis procedure combination database , 2015, BMC Musculoskeletal Disorders.
[2] S. Xiao,et al. Evaluation of the Aspartate Aminotransferase/Platelet Ratio Index and Enhanced Liver Fibrosis Tests to Detect Significant Fibrosis Due to Chronic Hepatitis C , 2014, Journal of clinical gastroenterology.
[3] J. Fallowfield,et al. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. , 2014, Journal of hepatology.
[4] T. Saibara,et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients , 2014, Journal of Gastroenterology.
[5] M. Abrahamowicz,et al. Profile of the Risk of Death After Septic Shock in the Present Era: An Epidemiologic Study , 2013, Critical care medicine.
[6] L. Baddour,et al. Predictive scoring model of mortality in Gram-negative bloodstream infection. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[7] G. Zararsiz,et al. Noninvasive assessment of liver damage in chronic hepatitis B. , 2013, World journal of hepatology.
[8] Q. Anstee,et al. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification , 2013, Journal of Clinical Pathology.
[9] Hirotaka Chikuda,et al. Incidence and risk factors for mortality of vertebral osteomyelitis: a retrospective analysis using the Japanese diagnosis procedure combination database , 2013, BMJ Open.
[10] M. Gönen,et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. , 2013, Journal of the American College of Surgeons.
[11] P. Gill,et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. , 2013, Journal of hepatology.
[12] W. Kratzer,et al. Percutaneous ultrasonographically guided liver punctures: an analysis of 1961 patients over a period of ten years , 2012, BMC Gastroenterology.
[13] A. Tsung,et al. Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: A case‐control study , 2012, Hepatology.
[14] N. Chalasani,et al. Erratum: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology (Gastroenterology (2012) 142 (1592-1609)) , 2012 .
[15] Robert D. Goldin,et al. The epidemiology, pathogenesis and histopathology of fatty liver disease , 2012, Histopathology.
[16] A. Diehl,et al. Mechanisms of disease progression in NASH: new paradigms. , 2012, Clinics in liver disease.
[17] H. Ferral,et al. Transjugular Liver Biopsy , 2012, Seminars in Interventional Radiology.
[18] Michael Charlton,et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.
[19] T. Saibara,et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population , 2011, BMC Gastroenterology.
[20] A. Szymczak,et al. Safety and Effectiveness of Blind Percutaneous Liver Biopsy: Analysis of 1412 Procedures , 2012, Hepatitis monthly.
[21] J. Rhee,et al. Liver cirrhosis as a risk factor for mortality in a national cohort of patients with bacteremia. , 2011, The Journal of infection.
[22] Ned C. Rouze,et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. , 2011, Journal of hepatology.
[23] N. Chalasani,et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.
[24] K. Brundyn,et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. , 2011, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[25] M. Stepanova,et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[26] Joel Z Stengel,et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.
[27] M. Krawczyk,et al. Nonalcoholic fatty liver disease. , 2010, Best practice & research. Clinical gastroenterology.
[28] A. Burt,et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease , 2022 .
[29] Rocio Lopez,et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.
[30] S. Grundy,et al. The metabolic syndrome. , 2008, Endocrine reviews.
[31] F. Schick,et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. , 2009, Journal of hepatology.
[32] J. Vauthey,et al. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. , 2009, The Lancet. Oncology.
[33] M. Michael,et al. Part II: Liver function in oncology: towards safer chemotherapy use. , 2008, The Lancet. Oncology.
[34] M. Michael,et al. Part I: Liver function in oncology: biochemistry and beyond. , 2008, The Lancet. Oncology.
[35] A. Loaeza-del-Castillo,et al. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. , 2008, Annals of hepatology.
[36] A. Shahrokni,et al. Gemcitabine-induced liver fibrosis in a patient with pancreatic cancer. , 2007, JOP : Journal of the pancreas.
[37] M. Choti,et al. Preoperative Chemotherapy for Colorectal Liver Metastases: Impact on Hepatic Histology and Postoperative Outcome , 2007, Journal of Gastrointestinal Surgery.
[38] T. Pawlik,et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] L. Rubbia‐Brandt,et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] M. Schiff,et al. CASE REPORT: Fatal Cholestatic Liver Failure Associated with Gemcitabine Therapy , 2003, Digestive Diseases and Sciences.
[41] D. Mannino,et al. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. , 2003, Chest.
[42] J. Kalbfleisch,et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.
[43] Erick M Remer,et al. The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.
[44] R. Wiesner,et al. Ultrasound-assisted percutaneous liver biopsy performed by a physician assistant. , 2002 .
[45] M. Perry,et al. Hepatotoxicity of chemotherapy. , 2001, Expert opinion on drug safety.
[46] R. Reznek,et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. , 1998, British Journal of Cancer.
[47] C. Day,et al. Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.
[48] Jones Sf,et al. Topoisomerase I inhibitors: topotecan and irinotecan. , 1996, Cancer practice.
[49] C. Fenger,et al. Reversible hepatic steatosis in patients treated with interferon alfa‐2A and 5‐fluorouracil , 1995, Cancer.
[50] J. Beijnen,et al. Taxanes: a new class of antitumor agents. , 1995, Cancer investigation.
[51] J. Verweij,et al. Topoisomerase I inhibitors: topotecan and irenotecan. , 1994, Cancer treatment reviews.
[52] T. Fleming,et al. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] F. Carnot,et al. Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. , 1991, Journal of hepatology.
[54] J. Goldberg,et al. Cyclophosphamide-associated hepatotoxicity. , 1985, Southern medical journal.
[55] A. Avilés,et al. Hepatic injury during doxorubicin therapy. , 1984, Archives of pathology & laboratory medicine.
[56] D. Johnson,et al. Etoposide-induced hepatic injury: a potential complication of high-dose therapy. , 1983, Cancer treatment reports.
[57] N. Hill,et al. Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases. , 1975, Cancer chemotherapy reports.